GOLDMAN SACHS GROUP INC - LIGAND PHARMACEUTICALS INC ownership

LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 199 filers reported holding LIGAND PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of LIGAND PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$4,184,872
-45.6%
69,841
-34.6%
0.00%
-50.0%
Q2 2023$7,699,848
+68.9%
106,794
+72.3%
0.00%
+100.0%
Q1 2023$4,560,058
+10.6%
61,991
+0.4%
0.00%0.0%
Q4 2022$4,124,566
+34.0%
61,745
+72.7%
0.00%0.0%
Q3 2022$3,079,000
-20.7%
35,758
-17.9%
0.00%0.0%
Q2 2022$3,885,000
-35.9%
43,546
-19.1%
0.00%0.0%
Q1 2022$6,058,000
-55.4%
53,859
-38.7%
0.00%
-66.7%
Q4 2021$13,574,000
+61.4%
87,876
+45.6%
0.00%
+50.0%
Q3 2021$8,409,000
-34.5%
60,357
-38.3%
0.00%
-33.3%
Q2 2021$12,835,000
-49.8%
97,836
-41.7%
0.00%
-50.0%
Q1 2021$25,591,000
-39.9%
167,871
-60.8%
0.01%
-45.5%
Q4 2020$42,583,000
+2.5%
428,186
-1.8%
0.01%
-8.3%
Q3 2020$41,554,000
-12.9%
435,934
+2.2%
0.01%
-20.0%
Q2 2020$47,696,000
+233.3%
426,425
+116.7%
0.02%
+200.0%
Q1 2020$14,310,000
-69.2%
196,780
-55.8%
0.01%
-58.3%
Q4 2019$46,441,000
+28.5%
445,303
+22.6%
0.01%
+9.1%
Q3 2019$36,149,000
-25.3%
363,153
-14.4%
0.01%
-21.4%
Q2 2019$48,403,000
-22.6%
424,032
-14.8%
0.01%
-26.3%
Q1 2019$62,545,000
+47.1%
497,540
+58.8%
0.02%
+35.7%
Q4 2018$42,521,000
-30.9%
313,348
+39.8%
0.01%
-12.5%
Q3 2018$61,511,000
-19.5%
224,091
-39.2%
0.02%
-23.8%
Q2 2018$76,370,000
+73.6%
368,632
+38.4%
0.02%
+90.9%
Q1 2018$43,992,000
+44.9%
266,363
+20.1%
0.01%
+57.1%
Q4 2017$30,363,000
-16.1%
221,743
-16.5%
0.01%
-22.2%
Q3 2017$36,173,000
+8.5%
265,683
-3.2%
0.01%0.0%
Q2 2017$33,330,000
+22.2%
274,551
+6.5%
0.01%
+28.6%
Q1 2017$27,285,000
+48.9%
257,797
+43.0%
0.01%
+40.0%
Q4 2016$18,319,000
-21.0%
180,282
-20.7%
0.01%
-28.6%
Q3 2016$23,199,000
+527.7%
227,306
+633.5%
0.01%
+600.0%
Q2 2016$3,696,000
+57.1%
30,989
+41.0%
0.00%0.0%
Q1 2016$2,353,000
+140.8%
21,972
+143.9%
0.00%
Q4 2015$977,000
-69.7%
9,007
-76.1%
0.00%
-100.0%
Q3 2015$3,222,000
-65.4%
37,610
-59.2%
0.00%
-66.7%
Q2 2015$9,306,000
-67.2%
92,236
-74.9%
0.00%
-66.7%
Q1 2015$28,374,000
+157.6%
367,973
+77.7%
0.01%
+200.0%
Q4 2014$11,016,000
-9.9%
207,025
-20.4%
0.00%
-25.0%
Q3 2014$12,220,000
-21.9%
260,037
+3.5%
0.00%0.0%
Q2 2014$15,654,000
+83.4%
251,322
+98.1%
0.00%
+33.3%
Q1 2014$8,536,000
-12.8%
126,883
-31.8%
0.00%
-25.0%
Q4 2013$9,790,000
+164.2%
186,120
+117.4%
0.00%
+300.0%
Q3 2013$3,706,000
-41.2%
85,615
-49.2%
0.00%
-66.7%
Q2 2013$6,307,000
+275.9%
168,632
+108.3%
0.00%
+200.0%
Q4 2012$1,678,000
+20.9%
80,947
+0.0%
0.00%0.0%
Q3 2012$1,388,000
+21.8%
80,911
+20.3%
0.00%0.0%
Q2 2012$1,140,000
+603.7%
67,276
+564.0%
0.00%
Q1 2012$162,00010,1320.00%
Other shareholders
LIGAND PHARMACEUTICALS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Knott David M Jr 115,000$12,937,0004.12%
Stonepine Capital Management, LLC 73,700$8,291,0003.44%
VILLERE ST DENIS J & CO LLC 510,843$57,464,0003.41%
Chicago Capital, LLC 491,717$55,313,0002.38%
Orchard Capital Management, LLC 73,596$8,279,0002.35%
RICE HALL JAMES & ASSOCIATES, LLC 344,969$38,806,0001.55%
Smith, Graham & Co., Investment Advisors, LP 86,834$9,768,0001.02%
WOODSTOCK CORP 64,050$7,205,0000.84%
INVESTMENT MANAGEMENT OF VIRGINIA LLC 37,246$4,190,0000.74%
Stephens Investment Management Group LLC 417,670$46,984,0000.69%
View complete list of LIGAND PHARMACEUTICALS INC shareholders